Q2 revenue up 33%, profit more than doubles; Rs 1 dividend declared

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹2181.90

prior close

₹2184.60

announcement price

In-mkt

timing

Nifty Midcap 150market+0.9%+2.0% vs market

Pharmaceuticals peers, median of 171sector+0.4%+2.5% vs sector

On the reaction day the stock moved 2.0 pts more than Nifty Midcap 150 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.5

15m

+2.2

30m

+2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8+0.9+2.0+0.4+2.5

Next day

+10.2pendingpending-0.7+10.9

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Laurus Labs posted unaudited Q2 FY27 consolidated revenue of Rs 2,206.37 crore, up 33.4% year on year, and profit after tax of Rs 436.74 crore versus Rs 193.75 crore, up 125.4%. H1 revenue rose 31.3% to Rs 4,232.68 crore and profit after tax rose 125.1% to Rs 798.73 crore. Operating cash flow was positive at Rs 253.81 crore. Interim dividend: Rs 1 per share, record date November 6, payment from November 19. Review was unmodified.

Likely market impact

Strong growth, cash flow and the dividend may support sentiment, but the stock reaction will depend on margin sustainability and guidance.